Results 11 to 20 of about 2,152,109 (243)

Risk of Posterior Capsular Rupture during Phacoemulsification in Patients with the History of Anti-VEGF Intravitreal Injections: Results from the Pan-American Collaborative Retina Study (PACORES) Group

Journal of Ophthalmology, 2021
Purpose. To assess the risk for capsular rupture during routine phacoemulsification in patients with a history of anti-VEGF injections and other possible risk modifiers such as treatment patterns, type of anti-VEGF agent, and experience of the surgeon ...
Raul Velez-Montoya, Idaira Sanchez-Santos, Mauricio Galvan-Chavez, Lihteh Wu, J. Fernando Arevalo, María H. Berrocal, Arturo A. Alezzandrini, Marta S. Figueroa, Roberto Gallego-Pinazo, Rosa Dolz-Marco, Clara Martinez-Rubio, Roberto Gonzalez-Salinas   +11 more
doaj   +2 more sources

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)

Clinical Ophthalmology, 2018
J Michael Jumper,1 Pravin U Dugel,2,3 Sanford Chen,4 Kevin J Blinder,5 John G Walt6 On behalf of the ECHO Study Group 1West Coast Retina Medical Group, San Francisco, CA, USA; 2Retinal Consultants of Arizona, Phoenix, AZ, USA; 3USC Roski Eye Institute,
Jumper JM, Dugel PU, Chen S, Blinder KJ, Walt JG   +4 more
doaj   +1 more source

Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti-VEGF

Journal of Ophthalmology, 2021
Background/Objectives. Currently, in England, antivascular endothelial growth factor (anti-VEGF) is the first-line treatment for diabetic macular oedema (DMO) where central macular thickness (CMT) is ≥400 microns.
Di Zou, Imran Jawaid, Winfried M. Amoaku
doaj   +1 more source

Modulated anti-VEGF therapy under the influence of lipid metabolizing proteins in Age related macular degeneration: a pilot study

Scientific Reports, 2022
Age-related macular degeneration (AMD) is a devastating retinal disease that results in irreversible vision loss in the aged population. The complex genetic nature and degree of genetic penetrance require a redefinition of the current therapeutic ...
Kaushal Sharma, Priya Battu, Ramandeep Singh, Suresh Kumar Sharma, Akshay Anand   +4 more
doaj   +1 more source

Trends, geographical variation and factors associated with the use of anti-VEGF intravitreal injections in Portugal (2013–2018): a retrospective analysis of administrative data

BMJ Open, 2022
Aims The arrival of anti-vascular endothelial growth factor (anti-VEGF) therapies represented a treatment shift for several ophthalmological disorders and led to an increasing number of patients undergoing intravitreal injections.
Ana Patricia Marques, Rui Santana, António Filipe Macedo, Pedro Laires, João Victor Rocha, Marta Afonso-Silva, Ana Sofia Almeida, Julieta Fernandes, Marisa Pardal   +8 more
doaj   +1 more source

Improving blood flow in occluded veins to reduce anti-vascular endothelial growth factor injections for branch retinal vein occlusion

American Journal of Ophthalmology Case Reports, 2023
Purpose: To assess the relationship between improving blood flow via arteriovenous (AV) sheathotomy without vitrectomy and the total number of anti-vascular endothelial growth factor injections (VEGF) required to treat branch retinal vein occlusion (BRVO)
Takatoshi Maeno, Kenichiro Aso, Ryuya Hashimoto, Hidetaka Masahara   +3 more
doaj   +1 more source

New Therapies of Neovascular AMD beyond Anti-VEGF Injections [PDF]

Vision (Switzerland), 2018
Arshad M Khanani, Greggory Gahn
exaly   +2 more sources

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis. [PDF]

Clin Ophthalmol, 2018
Szilárd Kiss,1 Pravin U Dugel,2,3 Arshad M Khanani,4 Michael S Broder,5 Eunice Chang,5 Gordon H Sun,5 Adam Turpcu6 1Department of Ophthalmology, Weill Cornell Medical College, New York, NY, USA; 2Retinal Consultants of Arizona, Phoenix, AZ, USA ...
Kiss S, Dugel PU, Khanani AM, Broder MS, Chang E, Sun GH, Turpcu A.   +6 more
europepmc   +2 more sources

Anti-vascular endothelial growth factor monotherapy or combined with verteporfin photodynamic therapy for retinal angiomatous proliferation: a systematic review with meta-analysis

Frontiers in Pharmacology, 2023
Purpose: To assess functional and anatomical outcomes of intravitreal anti-Vascular Endothelial Growth Factor (anti-VEGF) monotherapy versus combined with verteporfin Photodynamic Therapy (PDT) for Retinal Angiomatous Proliferation (RAP).Methods: Studies
Matteo Fallico, Iacopo Macchi, Andrea Maugeri, Giuliana Favara, Martina Barchitta, Roberta Magnano San Lio, Antonella Agodi, Andrea Russo, Antonio Longo, Teresio Avitabile, Niccolò Castellino, Michele Reibaldi, Francesco Pignatelli, Maria Vadalà, Clara Patanè, Marcella Nebbioso, Vincenza Bonfiglio   +16 more
doaj   +1 more source

Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy

American Journal of Ophthalmology Case Reports, 2022
Purpose: Myeloproliferative neoplasms (MPNs) have been associated with increased systemic levels of vascular endothelial growth factor (VEGF). This study investigated an association between systemic busulfan for treatment of MPN and the requirement for ...
Lauren A. Dalvin, Timothy W. Olsen, Sophie J. Bakri, Kristen McCullough, Ayalew Tefferi, Aref Al-Kali   +5 more
doaj   +1 more source